• English
    • svenska
  • English 
    • English
    • svenska
  • Login
View Item 
  •   Home
  • Sahlgrenska Academy / Sahlgrenska akademin
  • Institute of Medicine / Institutionen för medicin
  • Doctoral Theses / Doktorsavhandlingar Institutionen för medicin
  • View Item
  •   Home
  • Sahlgrenska Academy / Sahlgrenska akademin
  • Institute of Medicine / Institutionen för medicin
  • Doctoral Theses / Doktorsavhandlingar Institutionen för medicin
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Diffuse large B-cell lymphoma - proteomic and metabolomic studies on prognosis and treatment failure

Abstract
Abstract Background and aim: Every year almost 600 patients in Sweden are diagnosed with diffuse large B-cell lymphoma (DLBCL), the most common lymphoma, and with immunochemotherapy, approximately 60 % are cured. Yet, for patients with primary refractory disease or early relapse, the prognosis is very poor. Despite advances in molecular subclassification of DLBCL, the major tool used to risk stratify patients is the clinically based International Prognostic Index (IPI). However, there is still no available system that with precision can identify the individual patients at highest risk of treatment failure. The aim of this thesis was to search for novel prognostic and predictive biomarkers, and also investigate the mechanisms behind chemoresistance in DLBCL. Patients and methods: In paper I and III, tumor tissue from two groups of DLBCL patients; (i) patients with primary refractory disease or early relapse (REF/REL; paper I: n=5, paper III: n=44); and (ii) long-term progression-free patients, clinically considered cured (CURED; paper I: n=5, paper III: n=53), was examined with mass spectrometry proteomic approaches to explore possible differences in global protein expression, but also with the aim to reveal new mechanisms involved in immunochemotherapy resistance. In paper II, metabolomic examination with nuclear magnetic resonance spectroscopy was performed on serum from REF/REL (n=27) and CURED (n=60) DLBCL patients, to determine if differences in clinical outcome could be correlated to diverse metabolomic profiles. Results and Conclusions: In paper I, a large number of proteins could be identified and quantified. Overexpression of actin-related proteins was found among the CURED patients, a finding that appeared to be confirmed in paper III, where in addition a novel discovery regarding overexpression of multiple ribosomal proteins in the REF/REL group was made. The findings suggest previously undescribed mechanisms for immunochemotherapy resistance in DLBCL patients. In paper II, differences in the serum metabolome was found between the two groups, that could be separated with multivariate statistical analyses. Even though the results are encouraging they need to be confirmed in larger unselected studies, with aims of further exploring actin-related and ribosomal proteins, not only as possible prognostic/predictive biomarkers, but also regarding their functional role in treatment resistance in DLBCL.
Parts of work
Ruetschi U, Stenson M, Hasselblom S, Nilsson-Ehle H, Hansson U, Fagman H, et al. SILAC-Based Quantitative Proteomic Analysis of Diffuse Large B-Cell Lymphoma Patients. International journal of proteomics. 2015;2015:841769, ::doi::10.1155/2015/841769
 
Stenson M, Pedersen A, Hasselblom S, Nilsson-Ehle H, Karlsson BG, Pinto R, et al. Serum nuclear magnetic resonance-based metabolomics and outcome in diffuse large B-cell lymphoma patients - a pilot study. Leuk Lymphoma. 2016:1-9, ::doi::10.3109/10428194.2016.1140164
 
Bram Ednersson S, Stenson M, Stern M, Enblad G, Fagman H, Nilsson-Ehle H, et al. Expression of ribosomal and actin network proteins and immunochemotherapy resistance in diffuse large B cell lymphoma patients. Br J Haematol. 2018, ::doi::10.1111/bjh.15259
 
Degree
Doctor of Philosophy (Medicine)
University
University of Gothenburg. Sahlgrenska Academy
Institution
Inst of Medicine. Department of Internal Medicine and Clinical Nutrition
Disputation
Fredagen den 23 november 2018, kl. 9.00, Patologens Föreläsningssal, Sahlgrenska, Ehrenströmsgatan 1, Göteborg.
Date of defence
2018-11-23
E-mail
martin.stenson@vgregion.se
URI
http://hdl.handle.net/2077/56918
Collections
  • Doctoral Theses / Doktorsavhandlingar Institutionen för medicin
  • Doctoral Theses from Sahlgrenska Academy
  • Doctoral Theses from University of Gothenburg / Doktorsavhandlingar från Göteborgs universitet
View/Open
Thesis frame (16.94Mb)
Abstract (107.8Kb)
Cover (4.627Mb)
Date
2018-11-05
Author
Stenson, Martin
Keywords
DLBCL
prognostics
proteomics
metabolomics
Publication type
Doctoral thesis
ISBN
978-91-7833-153-6
978-91-7833-154-3
http://hdl.handle.net/2077/56918
Language
eng
Metadata
Show full item record

DSpace software copyright © 2002-2016  DuraSpace
Contact Us | Send Feedback
Theme by 
Atmire NV
 

 

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

My Account

LoginRegister

DSpace software copyright © 2002-2016  DuraSpace
Contact Us | Send Feedback
Theme by 
Atmire NV